登录新浪财经APP 搜索【信披】查看更多考评等级 1.案件所处的诉讼阶段：一审法院已立案受理，案号为(2026)京0108民初2924号，案由为买卖合同纠纷 案，本案暂未开庭审理。 2.上市公司下属控股子公司所处的当事人地位：原告。 3.涉案的金额：合同款人民币2,000万元、资金占用损失（含违约责任）；及相关律师费、保全费、保全 担保费、诉讼费等全部费用。 4.对上市公司损益产生的影响：目前该案件尚未判决，公司尚无法判断最终诉讼结果。最终结果对公司 本期利润或期后利润的影响尚存在不确定性。 一、本次重大诉讼受理的基本情况 古汉医药集团股份公司（以下简称"公司"）下属控股子公司湖南启迪药业生物有限公司（以下简称"原 告"、"子公司"）向北京市海淀区人民法院递交民事起诉状，起诉宁波医多多电子商务有限公司退还合 同款，同时诉福州市乐拓企业管理有限公司、北京涂多多电子商务股份有限公司依法承担连带责任，北 京市海淀区人民法院已受理本案，现对本案情况予以公告。 被告三：北京涂多多电子商务股份有限公司 （二）本案基本情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重 ...

Group 1 - The controlling shareholder and actual controller's concerted action partner, Changsha Tongjia Investment Management Partnership (Limited Partnership), plans to reduce its holdings in Dajia Weikang (301126.SZ) by up to 6.162 million shares, accounting for 3.00% of the company's total share capital [1] - The reduction will take place within three months from March 10, 2026, to June 9, 2026, through centralized bidding and block trading methods [1] - The announcement marks a significant move by the major shareholder, indicating potential changes in the company's ownership structure [1]

智通财经APP讯，华润医药(03320)发布天士力医药截至2025年12月31日止年度的未经审核初步财务资 料，天士力医药实现总营业收入人民币82.36亿元，同比下降3.08%，实现归属于上市公司股东的净利润 人民币11.05亿元，同比增长15.68%。从变动幅度上看，公司营业收入同比下降的主要原因是医药商业 收入(主要为连锁药店业务)受"门诊统筹"等行业性政策的影响同比减少14.24%。 ...

Group 1 - The controlling shareholder of Dajia Weikang plans to reduce its stake by up to 6.16 million shares, representing 3% of the company's total share capital, within a specified period from March 10, 2026, to June 9, 2026 [1] - The current shareholding of the controlling shareholder is 9.8 million shares, which accounts for 4.77% of the total share capital [1] Group 2 - A central bank, which has been increasing its gold reserves for two consecutive years, announced plans to purchase an additional 150 tons of gold [2] - The central bank's target is to accumulate a total of 700 tons of gold [2]

Group 1 - The core point of the article is that Changsha Tongjia Investment Management Partnership, a concerted action party of the controlling shareholder and actual controller of Dajia Weikang, plans to reduce its holdings in the company by up to 6.162096 million shares, which represents 3.00% of the total share capital [1] - The reduction will take place within a three-month period from March 10, 2026, to June 9, 2026, following a 15 trading day period after the announcement [1] - The current shareholding of Changsha Tongjia is 9.8 million shares, accounting for 4.77% of the company's total share capital [1]

Core Viewpoint - A major pharmaceutical company, Zhongyao Holdings, has come under scrutiny due to tax issues, with a total of 76.2 million yuan in tax payments required over two instances, raising concerns about its internal control and compliance capabilities [1][2]. Tax Compliance Concerns - The tax payments relate to the "Western Development Corporate Income Tax Incentive Policy," which allows a reduced tax rate of 15% for qualifying businesses, but requires that 60% of revenue comes from encouraged industries [2]. - The repeated tax payments suggest potential systemic issues in the company's judgment regarding the applicability of tax incentives, indicating possible inconsistencies in understanding the policy among subsidiaries [2]. Financial Impact and Cash Flow Pressure - While the tax payment amount may not significantly impact the overall performance of the group, which has annual revenues exceeding 80 billion yuan, the associated financial risks are notable [3]. - The late payment penalties, which accrue at a daily rate of 0.05% (approximately 18.25% annually), highlight a disconnect between financial planning and tax compliance, suggesting that the company may not have adequately reserved funds for tax liabilities [3]. Governance Structure and Internal Control Issues - Zhongyao Holdings operates under a dual-entity structure, which may lead to uneven control over subsidiaries and potential management challenges [4]. - The involvement of 29 subsidiaries in tax issues indicates that these risks are not isolated incidents, raising questions about the adequacy of guidance provided to subsidiaries regarding local tax regulations [4]. Conclusion - The ongoing tax payment issues at Zhongyao Holdings serve as a warning to all companies benefiting from regional tax incentives, emphasizing the need for rigorous compliance and management of tax-related matters [5]. - The market will be closely watching whether the company will conduct further tax self-assessments or adjust its business strategies in the western regions [5].

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [28][37]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.91% from January 23 to February 5, 2026, which is approximately 0.74 percentage points lower than the index [12]. - Most sub-sectors within the industry recorded negative returns during the same period, with offline pharmacies and vaccine sectors showing the best performance, increasing by 3.01% and 0.12% respectively, while other sectors like biological products and chemical preparations saw declines of 3.28% and 3.27% [13]. - Approximately 34% of stocks in the industry recorded positive returns, while 66% experienced negative returns during the reporting period [14]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 51.00 times as of February 5, 2026, indicating a decrease in industry valuation [18]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.91% from January 23 to February 5, 2026 [12]. - Most sub-sectors recorded negative returns, with offline pharmacies and vaccines performing relatively well [13]. - About 34% of stocks in the industry had positive returns, with significant variations in individual stock performance [14]. - The industry valuation has decreased, with a PE ratio of approximately 51.00 times [18]. 2. Industry News - The 11th batch of national procurement results is set to be implemented in February, with notifications already released by 17 provinces [26]. - The National Medical Insurance Administration has issued a notice to accelerate the cultivation and opening of application scenarios in the medical insurance field [25]. 3. Company Announcements - Jianyou Co., Ltd. announced that its subsidiary received FDA approval for its product, sodium selenite injection [27]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector as part of the 14th Five-Year Plan, with ongoing policy support [28]. - Recommended sectors for investment include medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, hospital and diagnostic services, traditional Chinese medicine, innovative drugs, biological products, and CXO services [29].

Group 1 - Lazard Asset Management LLC increased its stake in China National Pharmaceutical Group (国药控股) by 1.16304 million shares at a price of HKD 20.699 per share, totaling approximately HKD 24.0738 million [1] - After the increase, Lazard's total shareholding in China National Pharmaceutical Group reached approximately 148 million shares, representing a stake of 11.06% [1]

Group 1 - The company held its first extraordinary general meeting of shareholders for 2026 on February 5, 2026, at a designated location in Nanjing [2][3] - All resolutions presented at the meeting were approved, including changes to the purpose of repurchased shares and amendments to the company's articles of association [4][5] - The meeting was conducted in compliance with relevant laws and regulations, with a legal opinion confirming the validity of the proceedings [5][6] Group 2 - The company decided to change the purpose of 39,852 repurchased shares from "for employee stock ownership plans or equity incentives" to "for cancellation and reduction of registered capital" [7][8] - Following the cancellation of the repurchased shares, the total share capital will decrease from 1,308,931,240 shares to 1,308,891,388 shares, and the registered capital will be reduced to 1,308,891,388 yuan [8] - Creditors have a 30-day period from the notification date to claim their debts or request guarantees, with specific documentation required for claims [9]

Group 1 - Lazard Asset Management LLC increased its stake in China National Pharmaceutical Group (01099) by 1,163,040 shares at a price of HKD 20.699 per share, totaling approximately HKD 24.0738 million [1] - Following the increase, Lazard's total shareholding in the company is approximately 148 million shares, representing a holding percentage of 11.06% [1]